Erasca Inc. Common Stock ERAS · Stock Open Erasca Inc. Common Stock in new tab
Erasca Inc. Common Stock Analysis (ERAS)
Is Erasca Inc. Common Stock a good investment? Erasca Inc. Common Stock (ERAS) is currently trading at 15.04 USD. Market analysts have a consensus price target of 24.11 USD. This suggests a potential upside from current levels.
Earnings Schedule: Erasca Inc. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.62.
Investor FAQ
Does Erasca Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Erasca Inc. Common Stock?
Erasca Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.90.
Company Profile
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Community Discussion